Free Trial
TSE:RVX

Resverlogix (RVX) Stock Price, News & Analysis

Resverlogix logo
C$0.04 -0.01 (-11.11%)
As of 04/17/2025 03:10 PM Eastern

About Resverlogix Stock (TSE:RVX)

Key Stats

Today's Range
C$0.04
C$0.04
50-Day Range
C$0.04
C$0.05
52-Week Range
C$0.04
C$0.10
Volume
277,003 shs
Average Volume
52,735 shs
Market Capitalization
C$7.92 million
P/E Ratio
N/A
Dividend Yield
7.02%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Receive RVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter.

RVX Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Resverlogix Corp. (RVXCF)
Closing Bell: Resverlogix Corp up on Tuesday (RVX)
Closing Bell: Resverlogix Corp flat on Wednesday (RVX)
See More Headlines

RVX Stock Analysis - Frequently Asked Questions

Resverlogix's stock was trading at C$0.06 at the beginning of the year. Since then, RVX shares have decreased by 27.3% and is now trading at C$0.04.
View the best growth stocks for 2025 here
.

Resverlogix Corp. (TSE:RVX) released its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.03) EPS for the quarter.

Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Antibe Therapeutics (ATE), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT) and Burcon NutraScience (BU).

Company Calendar

Last Earnings
11/12/2024
Today
4/18/2025

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:RVX
CIK
N/A
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-2,808,530.87
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.00 per share
Price / Cash Flow
132.50
Book Value
C($0.23) per share
Price / Book
-0.17

Miscellaneous

Free Float
N/A
Market Cap
C$7.92 million
Optionable
Not Optionable
Beta
0.71
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (TSE:RVX) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners